Search
Close this search box.
Follow us

Product

Related

Products

Fingolimod.HCl

Multiple Sclerosis

Cas No: 162359-56-0

Mechanism Of Action: Active form of fingolimod binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5. And blocks the lymphocytes’ ability to emerge from

Dimethyl fumarate

Multiple Sclerosis

Cas No: 624-49-7

Mechanism Of Action: It acts centrally by activating the nuclear factor erythroid 2 related factor 2 (Nrf2) transcriptional pathway, which regulates enzymes that reduce oxidative stress.

Teriflunomide

Multiple Sclerosis

Cas No: 163451-81-8

Mechanism Of Action: It’s a selective and reversible inhibitor of dihydro-orotate dehydrogenase, which is a key mitochondrial enzyme in the de novo pyrimidine synthesis pathway, leading

Sitagliptin phosphate monohydrate

Anti-Diabetic

Cas No: 654671-77-9

Mechanism Of Action: Sitagliptin functions by stimulating insulin production and reducing the excessive production of glucose in the liver. It achieves this by prolonging the

Linagliptin

Anti-Diabetic

Cas No: 668270-12-0

Mechanism Of Action: Linagliptin is a competitive, reversible DPP-4 inhibitor. Inhibition of this enzyme slows the breakdown of GLP-1 and glucose-dependant insulinotropic polypeptide (GIP). GLP-1

Dapagliflozin propandiol.H2O

Anti-Diabetic

Cas No: 960404-48-2

Mechanism Of Action: Dapagliflozin inhibits the sodium-glucose contransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron. SGLT2 facilitates 90% of glucose

Empagliflozin

Anti-diabetic

Cas No: 864070-44-0

Mechanism Of Action: The vast majority of glucose filtered through the glomerulus is reabsorbed within the proximal tubule, primarily via SGLT2 (sodium-glucose linked co-transporter-2) which

ABIRATERONE ACETATE

ABIRATERONE ACETATE

Oncology

Cas No: 154229-18-2

Mechanism Of Action: Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1, also known as 17 alpha-hydroxylase/C17,20 lyase. It exerts its inhibitory effects

IXAZOMIB CITRATE

IXAZOMIB CITRATE

Oncology

Cas No: 1239908-20-3

Mechanism Of Action: Ixazomib functions by obstructing protein degradation through the inhibition of the 20S catalytic subunit of the 26S proteasome. Specifically, at lower concentrations,

VENETOCLAX

Oncology

Cas No: 1257044-40-8

Mechanism Of Action: Venetoclax, as the first and only BCL-2 inhibitor, plays a crucial role in restoring the apoptotic process in newly diagnosed acute myeloid